Adherence and patients' experiences with the use of erlotinib in NSCLC treatment: The influence on plasma concentration and the exploration of factors affecting the use in daily practice
Completed
- Conditions
- non-small-cell-lung cancer or lung cancer10038666
- Registration Number
- NL-OMON33122
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
NSCLC patients starting with erlotinib
Exclusion Criteria
younger than 18 year
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Adherence rate; a patient is adherent with the intake of 85% or more of the<br /><br>prescribed medication, the plasma concentration of erlotinib and the number and<br /><br>grade of side-effects.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Quality of life<br /><br>Attitude towards disease<br /><br>Beliefs and attitude towards medicines<br /><br>Percentage of dose adjustment and discontinuation</p><br>